

REMARKS

This communication is in response to the Restriction Requirement mailed on August 5, 2010.

I. Amendments to the Claims

Claims 1 and 38 are amended to include the step of performing a validation assay comprising determining proliferation of unfractionated peripheral blood mononuclear cells in response to the whole protein sequence of interest. Support for this language can be found, e.g., in original claims 13 and 47 (now canceled).

Claims 4 and 38 are amended to recite the formula used to determine structure values. Support for this language can be found, e.g., at page 47, lines 5-11, of the specification.

Claims 1 and 38 are amended to refer to monocyte cells rather than dendritic cells. Support for this language can be found, e.g., at page 16, lines 26-29 and page 44, lines 21-33, of the specification.

Claim 38 is amended to refer to sets of peptides rather than pepsets. Support for this language can be found, e.g., at page 24, lines 28-30, of the specification.

Claim 38 is amended to delete reference to CD8+ T-cells.

Claim 13-37 and 47 are canceled without prejudice or disclaimer.

The pending claims now substantially match the corresponding claims in European Patent Application No. 05779509.8, which is presently undergoing examination.

No new matter has been added by these amendments.

II. Response to Restriction Requirement

In the Restriction Requirement dated August 5, 2010, the Examiner required Applicants to elect one of two Groups of claims:

Group I: claims 1-13 and 38-47, drawn to a method for assessing immune response in animal populations, and

Group II: claims 14-37, drawn to a method for ranking the relative immunogenicity of two proteins.

In response, Applicants elect the claims of Group I, without traverse. The non-elected claims have been canceled.

III. Conclusion

Applicants believe that the present application is now in condition for examination. If the Examiner has any questions or believes that a telephone call would expedite Examination, she is encouraged to contact the undersigned.

The Director is hereby authorized to charge any fees under 37 C.F.R. §§ 1.16, 1.17, and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 07-1048 (Docket No. GC840-US).

Respectfully submitted,

Dated: November 4, 2010

/Stephen Todd/
Stephen Todd
Reg. No. 47,139

Danisco US Inc.
925 Page Mill Road
Palo Alto, CA 94304-1013
Tel.: 650-846-7595
Fax: 650-845-6504